Slate Pharmaceuticals Inc. has sold $1.99 million in mixed securities, according to an SEC filing, bringing its year's total financing to$4.78 million.
The Durham-based company, founded in 2007, is focuses on the acquisition, development and commercialization of products for the treatment of selected diseases and conditions of maturing men and women. Slate currently marketsTestopel in the United States, which is used to treat men with low testosterone.
Slate is led by President and CEO Robert Whitehead, who is set to receive about $300,000 of the offering's proceeds toward his salary. The rest of the money raised will be used for working capital.
In addition to Whitehead, principals named in the Reg D filing include directors Trygve Mikkelsen, who is founder and general partner of T+T Holdings LLC, a private investment company focused on private equity and hedge fund investments, and William Dahl, who is vice chairman and co-founder of Golden Pond Healthcare, a Darien, Conn.-based acquisition company focused on the health-care industry. Previously, Dahl was a managing director of the Carlyle Group, where he oversaw investing activities in the health-care industry.
Other directors named are Douglas Eckert, Michael Ford, Richard DeSchutter and Anthony Wild.
Slate Pharmaceuticals raised $2.79 million in January through a sale of mixed securities, according to a separate SEC filing.
No comments:
Post a Comment